Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?

IF 23 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Gut Pub Date : 2024-12-20 DOI:10.1136/gutjnl-2024-334069
Yenkai Lim, Seungha Kang, Ayesha Shah, Gerald Holtmann, Mark Morrison
{"title":"Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?","authors":"Yenkai Lim, Seungha Kang, Ayesha Shah, Gerald Holtmann, Mark Morrison","doi":"10.1136/gutjnl-2024-334069","DOIUrl":null,"url":null,"abstract":"We have read with interest the contribution by Bedke et al ,1 reporting changes in the stool microbiota associated with primary sclerosing cholangitis (PSC) in human and murine models of the disease. These changes coincide with an expansion of FoxP3+T reg cells, a response also linked with luminal butyrate concentrations and/or other goods and services arising from select commensal bacteria.2 Furthermore, the authors find patients with PSC with an associated IBD (PSC-IBD) as well as mice receiving faecal transfer from such patients experience a milder form of IBD, or attenuation of colitis, respectively. Their findings expand on those from Awoniyi et al , linking bile acid ecology and select stool bacteria deemed protective or pathogenic in a murine model of PSC, as well as an association of these microbial signatures with disease severity in patients with PSC.3 Attribution of the beneficial effects to the luminal/stool microbiota in both these studies was strengthened by their abrogation in mice following antibiotic administration. Interestingly, recent studies suggest that antibiotic treatment, and vancomycin administration in particular, can promote positive clinical benefits in both subjects with PSC and/or PSC-IBD regardless of age.4 Given the distinctive clinical features and epidemiology of PSC-IBD compared with IBD5 and the dichotomous impacts from antibiotics on disease course in different scenarios, …","PeriodicalId":12825,"journal":{"name":"Gut","volume":"56 1","pages":""},"PeriodicalIF":23.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/gutjnl-2024-334069","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We have read with interest the contribution by Bedke et al ,1 reporting changes in the stool microbiota associated with primary sclerosing cholangitis (PSC) in human and murine models of the disease. These changes coincide with an expansion of FoxP3+T reg cells, a response also linked with luminal butyrate concentrations and/or other goods and services arising from select commensal bacteria.2 Furthermore, the authors find patients with PSC with an associated IBD (PSC-IBD) as well as mice receiving faecal transfer from such patients experience a milder form of IBD, or attenuation of colitis, respectively. Their findings expand on those from Awoniyi et al , linking bile acid ecology and select stool bacteria deemed protective or pathogenic in a murine model of PSC, as well as an association of these microbial signatures with disease severity in patients with PSC.3 Attribution of the beneficial effects to the luminal/stool microbiota in both these studies was strengthened by their abrogation in mice following antibiotic administration. Interestingly, recent studies suggest that antibiotic treatment, and vancomycin administration in particular, can promote positive clinical benefits in both subjects with PSC and/or PSC-IBD regardless of age.4 Given the distinctive clinical features and epidemiology of PSC-IBD compared with IBD5 and the dichotomous impacts from antibiotics on disease course in different scenarios, …
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Gut
Gut 医学-胃肠肝病学
CiteScore
45.70
自引率
2.40%
发文量
284
审稿时长
1.5 months
期刊介绍: Gut is a renowned international journal specializing in gastroenterology and hepatology, known for its high-quality clinical research covering the alimentary tract, liver, biliary tree, and pancreas. It offers authoritative and current coverage across all aspects of gastroenterology and hepatology, featuring articles on emerging disease mechanisms and innovative diagnostic and therapeutic approaches authored by leading experts. As the flagship journal of BMJ's gastroenterology portfolio, Gut is accompanied by two companion journals: Frontline Gastroenterology, focusing on education and practice-oriented papers, and BMJ Open Gastroenterology for open access original research.
期刊最新文献
Correction: The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells Are histamine-2 receptor antagonists a reasonable comparator: comparing apples and apples? Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota Redefining QUAIDE: paving the way for better AI in preclinical endoscopy Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1